<DOC>
	<DOC>NCT02674763</DOC>
	<brief_summary>This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.</brief_summary>
	<brief_title>Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia</brief_title>
	<detailed_description>In the Dose Escalation Phase, patients will be assigned to one of two schedules. The MTD for both schedules will be determined from the assessment of Dose Limiting Toxicities (DLTs). The Dose Expansion Phase will consist of two cohorts based on patients response to prior therapy according to the MTD selected.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Dose Escalation: Patients with relapsed or refractory AML Dose Expansion Cohort 1: Patients with relapsed AML or patients who refuse, or ar not suitable candidates for induction therapy Dose Expansion Cohort 2: Patients with refractory AML Dose Escalation: Acute Promyelocytic Leukemia Any concurrent anticancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational agents (with the exception of hydroxyurea or leukapheresis for control of hyperleukocytosis) within 14 days or five halflives of drugs, whichever is shorter, prior to Cycle 1 Day 1 AML patients with known, active leptomeningeal/central nervous system (CNS) involvement Prior treatment with IMGN779 Women who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>IMGN779</keyword>
	<keyword>ImmunoGen</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>CD33</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Dose Expansion</keyword>
</DOC>